Companies · Other Health Care

Zyppah, Inc.

Carson City · Other Health Care

Diligence memoA one-page analyst read on Zyppah, Inc. — recommendation, valuation, rhythm, risks.
$4.6M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 39%
Sector rank · raised
Series A
Latest stage · inferred · Mon Apr 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Zyppah, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.03× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.
  • Issuer reports $1M–$5M revenue while modeled below niche peers.
At-risk
  • Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Zyppah, Inc. is one of 5377 Other Health Care companies tracked from Carson City. By capital raised it ranks mid-pack (ahead of 62% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(b)
Reg D exemption
13
Investors (latest)
2023-04-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeries A · 2016-07-01 Raised $4.5M (real) Modeled valuation $91M (est)$4.5M$91MSeries A2016Series A · 2023-04-17 Raised $125K (real) Modeled valuation $928K (est)$125K$928KSeries A2023Pre-Seed · 2023-04-17 Raised $125K (real) Modeled valuation $963K (est)$125K$963KPre-Seed2023+$125K+$125KCumulative $4.8M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.5M · 2016
Series A extension$125K · 2023
Bridge · Series A-stage$125K · 2023smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$928K
Base estimate est.
$160K
Conservative case
$2.7M
Upside case
$568K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $90.8M · 2016-07-012016Series A · modeled $928K · 2023-04-17Pre-Seed · modeled $963K · 2023-04-172023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
3.2 yr
Elapsed time used
3.2 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
41 mo
Avg between rounds
$681K/yr
Capital velocity
10.0 yr
On record since
2016
First round
3
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.9× above median
This company$4.6M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.0× of median
This company$125K
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$928K
Sector median$22.1M

Raised more than 62% of sector peers (real $). Modeled value above 6% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #196 of 196.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)CareHarmony, Inc. · Series A Raised $17.4M · modeled $145.2M (est)Dragonfly Endoscopy Inc. · Series A Raised $12.7M · modeled $142.0M (est)NuvoAir Holdings, Inc. · Series A Raised $10.7M · modeled $125.1M (est)Post Acute Recovery, Inc. · Series A Raised $14.5M · modeled $123.0M (est)Micro Interventional Devices, Inc. · Series A Raised $14.0M · modeled $119.0M (est)Etiometry Inc. · Series A Raised $15.6M · modeled $114.7M (est)SafKan, Inc. · Series A Raised $13.0M · modeled $108.5M (est)BehaVR Holdings, Inc. · Series A Raised $12.1M · modeled $102.1M (est)Outliers Inc. · Series A Raised $13.6M · modeled $101.7M (est)RevMedica, Inc. · Series A Raised $14.2M · modeled $101.2M (est)Innovoyce LLC · Series A Raised $9.9M · modeled $97.6M (est)Prixz, Inc. · Series A Raised $9.2M · modeled $97.4M (est)Zyppah, Inc. (this company) Raised $4.6M · modeled $928K (est)Zyppah, Inc.
CompanyStageRaised · realValue · estvs peer med.
CareHarmony, Inc.Series A$17.4M$145.2M3.96×
Dragonfly Endoscopy Inc.Series A$12.7M$142.0M3.87×
NuvoAir Holdings, Inc.Series A$10.7M$125.1M3.41×
Post Acute Recovery, Inc.Series A$14.5M$123.0M3.35×
Micro Interventional Devices, Inc.Series A$14.0M$119.0M3.25×
Etiometry Inc.Series A$15.6M$114.7M3.13×
SafKan, Inc.Series A$13.0M$108.5M2.96×
BehaVR Holdings, Inc.Series A$12.1M$102.1M2.78×
Outliers Inc.Series A$13.6M$101.7M2.77×
RevMedica, Inc.Series A$14.2M$101.2M2.76×
Innovoyce LLCSeries A$9.9M$97.6M2.66×
Prixz, Inc.Series A$9.2M$97.4M2.66×
Zyppah, Inc. this companySeries A$4.6M$928K0.03×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.5M2016-07-01$20.5M$90.8M85%
Series A$125K2023-04-17$568K$928K90%
Pre-Seed$125K2023-04-17$694K$963K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.5M2016-07-01
    • First recorded raise — entered as Series A.
  2. Series A$125K2023-04-17
    • Raised again after 82 mo — slower than the ~14 mo sector norm.
    • Round 36.0× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 13 investors on this round.
  3. Pre-Seed$125K2023-04-17
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 13 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~41mo cadence
$125K
Modeled next size est.range $125K$200K
1.0×
Last step-up
$681K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jonathan Greenburg2016-07
Lawrence Biggs2023-04
Owen Gonzales2016-07
Registry & provenance

Zyppah, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1678008
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
USA Baldwin County ASC, LLCOther Health CareSeries A$5.2M$1.1Msame sector · same stage
B Positive Plasma LlcOther Health CareSeries A$5.2M$487Ksame sector · same stage
Vesteck, Inc.Other Health CareSeries A$7.0M$1.1Msame sector · same stage
Inspire Veterinary Partners, Inc.Other Health CareSeries A$8.9M$1.2Msame sector · same stage
Treasure Valley Hospital Limited PartnershipOther Health CareSeries A$10.9M$368Ksame sector · same stage
Wellist, Inc.Other Health CareSeries A$12.8M$1.3Msame sector · same stage
Encision IncOther Health CareSeed$4.6M$1.4Msame sector
Pelvital Usa, Inc.Other Health CareSeed$4.7M$435Ksame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Zielbio, Inc.Other Health CareSeries A$68.8M87%
Zyus Life Sciences CorpOther Health CarePre-Seed$1.6M86%
Zyus Life Sciences Inc.Other Health CareSeries B$10.4M86%
Zorro-Flow, Inc.Other Health CarePre-Seed$3.4M86%
Zimmer Biomet Holdings, Inc.Other Health CareSeries D+$2.9B86%
Zygood,LLCOther Health CarePre-Seed$3.1M86%
XCath, Inc.Other Health CareSeries A$107.6M85%
Homh, Inc.Other Health CarePre-Seed$11.6M84%
Frequently asked
How much funding has Zyppah, Inc. raised?
Zyppah, Inc. has raised approximately $4.6M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Zyppah, Inc.'s estimated valuation?
Provath's modeled valuation for Zyppah, Inc. is approximately $928K (modeled range $160K–$2.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Zyppah, Inc. at?
Zyppah, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Apr 17.
What does Zyppah, Inc. do and where is it based?
Zyppah, Inc. operates in the Other Health Care sector, based in Carson City.
Explore related

See where Zyppah, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Zyppah, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.